Study analysis · Nutrients · 2022
Can a vitamin-like supplement really boost your memory? The science is more complicated than you think.
In animal studies, NAD+ supplements like NMN and NR improve memory, but human trials have shown mixed results—so it's too early to recommend them for preventing dementia.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study is like a librarian gathering reports from many mouse experiments and a few human tests. It can tell you what scientists have tried, but it can't prove whether taking these supplements will help your memory—that would need a big, carefully designed study in people.
What’s the bottom line?
This review looked at many studies on supplements called NAD+ precursors (like NMN and NR) that are thought to help brain cells stay healthy. Most studies were in mice and rats, and they found that these supplements improved memory and learning in animals with brain diseases like Alzheimer's or after a stroke. But when tested in people, the results were mixed—some studies showed benefits, others showed none.
How strong is this study?
This paper was written by one person who picked the studies they thought were important, but didn't follow a strict search plan like a detective would. That means some important studies might be missing, and we can't be sure the conclusions are completely fair. So trust it like a friend's opinion, not a proven fact.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 51 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
This design cannot establish causation — the findings describe an association, not a cause. Narrative review of primarily animal studies and a few human studies; no systematic methodology, no pooling of results, cannot infer causation in humans.
No Conflicts
No conflicts of interest identified
No conflicts of interest identified as no disclosure statements were provided.
The text is a review article summarizing existing research. It lacks conflict of interest declarations and funding statements, making it impossible to assess potential biases. However, no overt conflicts are mentioned.
Key takeaways
- 01
In animal studies, supplements like NMN and NR improved memory tests in old mice, diabetic rats, and mice with Alzheimer's.
- 02
But in a small human study, NADH (10 mg/day) did not improve memory in dementia patients.
- 03
Another study with 30 mg/day NADH in healthy men found no effect on concentration.
- 04
For humans, it's still unclear if these supplements work.
- 05
The animal results are promising, but the few human studies don't strongly support using them for memory protection yet.
- 06
More research is needed.
Surprising findings
- One study found that niacin deficiency actually improved spatial learning in rats—until niacin was restored.This is counterintuitive because niacin deficiency in humans causes pellagra, which includes severe cognitive impairment.
- A multi-center TBI study (OBTT) found that NAM treatment sometimes made cognitive outcomes worse in certain models.Most animal studies show benefit, but this large consortium found negative effects on working memory at low doses, dampening enthusiasm for clinical translation.
Practical takeaways
If you're considering NAD+ precursors for cognitive health, wait for more human trials. The evidence is too weak to recommend for or against.
The review includes null human results and some negative animal findings, so risk-benefit is unclear.
low confidenceFor acute brain injury (stroke/TBI), current evidence does not support using NAD+ supplements because the effective window is too narrow and human data are lacking.
Most studies used injections, not oral supplements, so bioavailability and dosing in humans remain unknown.
low confidenceWhy this study matters
NAD+ precursors show promise in animals
In rodent models of Alzheimer's, vascular dementia, aging, diabetes, stroke, and TBI, supplements like NMN and NR consistently improved learning and memory. For example, 24-month-old rats given NMN showed better working memory and cognitive flexibility.
If these results translate to humans, it could mean a simple supplement might protect against age-related cognitive decline.
Human evidence is scarce and conflicting
Only a handful of human trials exist. A 1996 open-label study of NADH in Alzheimer's patients showed cognitive improvement, but a 2000 trial found no effect. A small trial in healthy men found no improvement in concentration after 30 mg/day NADH for 4 weeks.
This highlights the gap between promising animal data and real-world human outcomes—a common problem in supplement research.
Timing matters: The stroke/TBI window is narrow
In rodent stroke and TBI models, NAD+ precursors (especially NAM) improved outcomes only if given within a few hours of injury. For TBI, cognitive recovery required treatment within 4 hours, while sensorimotor benefits lasted up to 8 hours.
This suggests that for acute events, supplementation must be immediate—not practical for most people who don't recognize symptoms right away.
Not all NAD+ precursors are equal—and side effects matter
Niacin (nicotinic acid) has been understudied due to its flushing and itching side effects. Other precursors like NR and NMN are better tolerated but still lack long-term safety data.
People often assume supplements are harmless, but niacin's side effects remind us that 'natural' doesn't mean risk-free.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This review looked at many studies on supplements called NAD+ precursors (like NMN and NR) that are thought to help brain cells stay healthy. Most studies were in mice and rats, and they found that these supplements improved memory and learning in animals with brain diseases like Alzheimer's or after a stroke. But when tested in people, the results were mixed—some studies showed benefits, others showed none.
Research results
In animal studies, supplements like NMN and NR improved memory tests in old mice, diabetic rats, and mice with Alzheimer's. But in a small human study, NADH (10 mg/day) did not improve memory in dementia patients. Another study with 30 mg/day NADH in healthy men found no effect on concentration.
What this means - more context
For humans, it's still unclear if these supplements work. The animal results are promising, but the few human studies don't strongly support using them for memory protection yet. More research is needed.
This narrative review summarizes evidence on NAD+ precursor supplementation (NR, NMN, NAM, NADH, niacin) for preserving cognitive function across conditions including Alzheimer's disease, vascular dementia, age-related decline, diabetes, stroke, and traumatic brain injury.
Preclinical studies predominantly in rodent models show that NAD+ precursors improve learning, memory, and other cognitive measures in Alzheimer's, vascular dementia, aging, diabetes, stroke, and TBI models. However, human trials are scarce and have yielded mixed results, with some showing no cognitive improvement. The review highlights the need for more controlled clinical research.
Methods Used
Narrative review of published studies on NAD+ precursor supplementation for cognitive decline, focusing on animal models and few human trials. No systematic search or meta-analysis was performed.
Main Finding
NAD+ precursors show consistent neuroprotective and cognitive benefits in rodent models across multiple disease contexts, but human data are limited and inconclusive, with some null findings.
Confidence Level
Moderate for preclinical efficacy; low for human translation due to lack of robust clinical trials.
Study Flags
Red Flags
- •Most evidence from animal models, few human trials
- •Conflicting results even within animal studies (some negative effects reported)
- •Narrow therapeutic windows in acute conditions like stroke and TBI limit clinical applicability
Surprising Findings
One study found that niacin deficiency actually improved spatial learning in rats—until niacin was restored.
This is counterintuitive because niacin deficiency in humans causes pellagra, which includes severe cognitive impairment.
Practical Takeaways
If you're considering NAD+ precursors for cognitive health, wait for more human trials. The evidence is too weak to recommend for or against.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 51 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
Narrative Review
Subject
Lower probability
on the GRADE evidence scale
This study is like a librarian gathering reports from many mouse experiments and a few human tests. It can tell you what scientists have tried, but it can't prove whether taking these supplements will help your memory—that would need a big, carefully designed study in people.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Covers multiple disease contexts
- Includes both positive and negative findings
- Discusses need for further research
Weaknesses
- Narrative review with no systematic search strategy
- No quality assessment of included studies
- Primarily animal studies with limited human data
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This review looked at many studies on supplements called NAD+ precursors (like NMN and NR) that are thought to help brain cells stay healthy. Most studies were in mice and rats, and they found that these supplements improved memory and learning in animals with brain diseases like Alzheimer's or after a stroke. But when tested in people, the results were mixed—some studies showed benefits, others showed none.
Research results
In animal studies, supplements like NMN and NR improved memory tests in old mice, diabetic rats, and mice with Alzheimer's. But in a small human study, NADH (10 mg/day) did not improve memory in dementia patients. Another study with 30 mg/day NADH in healthy men found no effect on concentration.
What this means - more context
For humans, it's still unclear if these supplements work. The animal results are promising, but the few human studies don't strongly support using them for memory protection yet. More research is needed.
This narrative review summarizes evidence on NAD+ precursor supplementation (NR, NMN, NAM, NADH, niacin) for preserving cognitive function across conditions including Alzheimer's disease, vascular dementia, age-related decline, diabetes, stroke, and traumatic brain injury.
Preclinical studies predominantly in rodent models show that NAD+ precursors improve learning, memory, and other cognitive measures in Alzheimer's, vascular dementia, aging, diabetes, stroke, and TBI models. However, human trials are scarce and have yielded mixed results, with some showing no cognitive improvement. The review highlights the need for more controlled clinical research.
Methods Used
Narrative review of published studies on NAD+ precursor supplementation for cognitive decline, focusing on animal models and few human trials. No systematic search or meta-analysis was performed.
Main Finding
NAD+ precursors show consistent neuroprotective and cognitive benefits in rodent models across multiple disease contexts, but human data are limited and inconclusive, with some null findings.
Confidence Level
Moderate for preclinical efficacy; low for human translation due to lack of robust clinical trials.
Study Flags
Red Flags
- •Most evidence from animal models, few human trials
- •Conflicting results even within animal studies (some negative effects reported)
- •Narrow therapeutic windows in acute conditions like stroke and TBI limit clinical applicability
Surprising Findings
One study found that niacin deficiency actually improved spatial learning in rats—until niacin was restored.
This is counterintuitive because niacin deficiency in humans causes pellagra, which includes severe cognitive impairment.
Practical Takeaways
If you're considering NAD+ precursors for cognitive health, wait for more human trials. The evidence is too weak to recommend for or against.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 51 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
Narrative Review
Subject
Lower probability
on the GRADE evidence scale
This study is like a librarian gathering reports from many mouse experiments and a few human tests. It can tell you what scientists have tried, but it can't prove whether taking these supplements will help your memory—that would need a big, carefully designed study in people.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Covers multiple disease contexts
- Includes both positive and negative findings
- Discusses need for further research
Weaknesses
- Narrative review with no systematic search strategy
- No quality assessment of included studies
- Primarily animal studies with limited human data
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This paper was written by one person who picked the studies they thought were important, but didn't follow a strict search plan like a detective would. That means some important studies might be missing, and we can't be sure the conclusions are completely fair. So trust it like a friend's opinion, not a proven fact.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 51 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
This design cannot establish causation — the findings describe an association, not a cause. Narrative review of primarily animal studies and a few human studies; no systematic methodology, no pooling of results, cannot infer causation in humans.
No Conflicts
No conflicts of interest identified
No conflicts of interest identified as no disclosure statements were provided.
The text is a review article summarizing existing research. It lacks conflict of interest declarations and funding statements, making it impossible to assess potential biases. However, no overt conflicts are mentioned.